Marshall Wace
SRPT icon

Marshall Wace’s Sarepta Therapeutics SRPT Stock Holding History

Marshall Wace’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-210,000
Closed -$8.96M – 1107
2016
Q3 		$8.96M Buy
+210,000
New +$6.35M 0.06% 305

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace's SRPT Position: Q2 2026 in Review

Marshall Wace increased its Sarepta Therapeutics (SRPT) stake by 204% in Q2 2026, buying an estimated $28M and bringing the position to 2,206,022 shares worth $39.6M. The position accounts for 0.03% of the portfolio, ranked #457.

Marshall Wace first reported a position in SRPT in Q1 2015 and has held it in 24 quarters since. The position peaked at $45.4M in Q4 2021. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Marshall Wace held 2,206,022 shares of Sarepta Therapeutics worth $39.6M as of Q2 2026.
  • Marshall Wace bought 1,480,954 Sarepta Therapeutics shares in Q2 2026, an estimated $28M.
  • Sarepta Therapeutics made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #457 holding.
  • Marshall Wace first reported a position in Sarepta Therapeutics in Q1 2015 and has held it in 24 quarters since.
  • Marshall Wace's Sarepta Therapeutics position peaked at $45.4M in Q4 2021.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.